Update on Q & A
Scandion Oncology wishes to make aware that we have published a new Q&A on August 20, 2019. The Q&A concerns the status on a EU grant regarding endocrine treatment of breast cancer cell lines. The Q&A can be read here: https://scandiononcology.com/qa/For more information regarding Scandion, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com www.scandiononcology.com Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective